Fintel reports that on December 12, 2025, Wells Fargo upgraded their outlook for Zymeworks (NasdaqGS:ZYME) from Equal-Weight to Overweight.
Analyst Price Forecast Suggests 38.11% Upside
As of December 6, 2025, the average one-year price target for Zymeworks is $35.19/share. The forecasts range from a low of $25.25 to a high of $44.10. The average price target represents an increase of 38.11% from its latest reported closing price of $25.48 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Zymeworks is 148MM, an increase of 10.25%. The projected annual non-GAAP EPS is -1.45.
What is the Fund Sentiment?
There are 331 funds or institutions reporting positions in Zymeworks. This is an decrease of 20 owner(s) or 5.70% in the last quarter. Average portfolio weight of all funds dedicated to ZYME is 0.15%, an increase of 4.04%. Total shares owned by institutions decreased in the last three months by 4.57% to 78,404K shares. 
The put/call ratio of ZYME is 0.88, indicating a bullish outlook.
What are Other Shareholders Doing?
EcoR1 Capital holds 22,970K shares representing 30.69% ownership of the company. No change in the last quarter.
Rubric Capital Management holds 4,711K shares representing 6.29% ownership of the company. No change in the last quarter.
Bvf holds 3,939K shares representing 5.26% ownership of the company. In its prior filing, the firm reported owning 4,309K shares , representing a decrease of 9.40%. The firm increased its portfolio allocation in ZYME by 41.15% over the last quarter.
Redmile Group holds 3,706K shares representing 4.95% ownership of the company. In its prior filing, the firm reported owning 4,151K shares , representing a decrease of 12.01%. The firm increased its portfolio allocation in ZYME by 11.08% over the last quarter.
Perceptive Advisors holds 2,091K shares representing 2.79% ownership of the company. In its prior filing, the firm reported owning 1,275K shares , representing an increase of 39.00%. The firm increased its portfolio allocation in ZYME by 62.24% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
